Huizinga, H.K.; Hooghiemstra, W.T.R.; Linssen, M.D.; Allersma, D.P.; Gareb, B.; Dekkers, B.G.J.; Nagengast, W.B.; Lub-de Hooge, M.N.
Development of Clinical-Grade Durvalumab-680LT and Nivolumab-800CW for Multispectral Fluorescent Imaging of the PD-1/PD-L1 Axis of the Immune Checkpoint Pathway. Pharmaceuticals 2025, 18, 1501.
https://doi.org/10.3390/ph18101501
AMA Style
Huizinga HK, Hooghiemstra WTR, Linssen MD, Allersma DP, Gareb B, Dekkers BGJ, Nagengast WB, Lub-de Hooge MN.
Development of Clinical-Grade Durvalumab-680LT and Nivolumab-800CW for Multispectral Fluorescent Imaging of the PD-1/PD-L1 Axis of the Immune Checkpoint Pathway. Pharmaceuticals. 2025; 18(10):1501.
https://doi.org/10.3390/ph18101501
Chicago/Turabian Style
Huizinga, Henrik K., Wouter T. R. Hooghiemstra, Matthijs D. Linssen, Derk P. Allersma, Bahez Gareb, Bart G. J. Dekkers, Wouter B. Nagengast, and Marjolijn N. Lub-de Hooge.
2025. "Development of Clinical-Grade Durvalumab-680LT and Nivolumab-800CW for Multispectral Fluorescent Imaging of the PD-1/PD-L1 Axis of the Immune Checkpoint Pathway" Pharmaceuticals 18, no. 10: 1501.
https://doi.org/10.3390/ph18101501
APA Style
Huizinga, H. K., Hooghiemstra, W. T. R., Linssen, M. D., Allersma, D. P., Gareb, B., Dekkers, B. G. J., Nagengast, W. B., & Lub-de Hooge, M. N.
(2025). Development of Clinical-Grade Durvalumab-680LT and Nivolumab-800CW for Multispectral Fluorescent Imaging of the PD-1/PD-L1 Axis of the Immune Checkpoint Pathway. Pharmaceuticals, 18(10), 1501.
https://doi.org/10.3390/ph18101501
